FEATURED COMPANIES
- Abionyx
- Asahi Kasei Pharma
- Cidara Therapeutics
- Enlivex Therapeutics
- Inotrem
- Revimmune
This “Sepsis - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sepsis: Overview
Sepsis is a life-threatning organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Implementing preventive measures against infections, such as good hygiene practices, ensuring access to vaccination programs, improved sanitation and water quality and availability, and other infection prevention and control best practices both in the community and health care settings, are key steps in reducing the occurrence of sepsis.
Symptoms
There are three stages of sepsis which are sepsis, severe sepsis, and septic shock. Symptoms of sepsis includes:
Diagnosis
Diagnosis of sepsis demands a high level of suspicion, through the study of history and physical examination, appropriate laboratory checkups, and close follow-up of hemodynamic status of the patient.
Treatment
Sepsis is a medical emergency. It needs to be treated as such. Sepsis should be treated as quickly and efficiently as possible as soon as it has been identified. Treatment includes rapid administration of antibiotics and fluids. The risk of death from sepsis increases by an average of up to 7.6% with every hour that passes before treatment begins.
"Sepsis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sepsis Emerging Drugs
Rezafungin: Cidara Therapeutics
Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.
VBI-S: Vivacelle Bio
VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.
Sepsis: Therapeutic Assessment
This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Sepsis
There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics.
Phases
This report covers around 40+ products under different phases of clinical development like
Sepsis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.
Sepsis Report Insights
Current Treatment Scenario and Emerging Therapies:
This report will be delivered within 2 business days.
Geography Covered
- Global coverage
Sepsis: Overview
Sepsis is a life-threatning organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Implementing preventive measures against infections, such as good hygiene practices, ensuring access to vaccination programs, improved sanitation and water quality and availability, and other infection prevention and control best practices both in the community and health care settings, are key steps in reducing the occurrence of sepsis.
Symptoms
There are three stages of sepsis which are sepsis, severe sepsis, and septic shock. Symptoms of sepsis includes:
- Fever above 101ºF (38ºC) or a temperature below 96.8ºF (36ºC)
- Heart rate higher than 90 beats per minute
- Breathing rate higher than 20 breaths per minute
- Probable or confirmed infection
Diagnosis
Diagnosis of sepsis demands a high level of suspicion, through the study of history and physical examination, appropriate laboratory checkups, and close follow-up of hemodynamic status of the patient.
Treatment
Sepsis is a medical emergency. It needs to be treated as such. Sepsis should be treated as quickly and efficiently as possible as soon as it has been identified. Treatment includes rapid administration of antibiotics and fluids. The risk of death from sepsis increases by an average of up to 7.6% with every hour that passes before treatment begins.
"Sepsis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.
This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sepsis Emerging Drugs
Rezafungin: Cidara Therapeutics
Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.
VBI-S: Vivacelle Bio
VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.
Sepsis: Therapeutic Assessment
This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Sepsis
There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics.
Phases
This report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Sepsis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.
Sepsis Report Insights
- Sepsis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sepsis drugs?
- How many Sepsis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sepsis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cidara Therapeutics
- Vivacelle Bio
- SciClone Pharmaceuticals
- Asahi Kasei Pharma
- Sanofi
- Shionogi
- Revimmune
- Inotrem
- Enlivex Therapeutics
- Abionyx
- Rezafungin
- VBI-S
- Thymosin alpha 1
- ART-123
- Alirocumab
- Cefiderocol
- CYT107
- Nangibotide
- Allocetra-OTS
- CER-001
This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abionyx
- Asahi Kasei Pharma
- Cidara Therapeutics
- Enlivex Therapeutics
- Inotrem
- Revimmune
Introduction
Executive Summary
Sepsis: Overview
In-depth Commercial Assessment
Sepsis Key Products
Sepsis- Unmet Needs
Sepsis- Market Drivers and Barriers
Sepsis- Future Perspectives and Conclusion
Sepsis Analyst Views
Sepsis Key Companies
Appendix
List of Tables
Table 1 Total Products for Sepsis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Sepsis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Sepsis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Sepsis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Sepsis Key Products
Sepsis- Unmet Needs
Sepsis- Market Drivers and Barriers
Sepsis- Future Perspectives and Conclusion
Sepsis Analyst Views
Sepsis Key Companies
Appendix
List of Tables
Table 1 Total Products for Sepsis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Sepsis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
- Cidara Therapeutics
- Vivacelle Bio
- SciClone Pharmaceuticals
- Asahi Kasei Pharma
- Sanofi
- Shionogi
- Revimmune
- Inotrem
- Enlivex Therapeutics
- Abionyx
Note: Product cover images may vary from those shown
